Sirolimus
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
1
Recruiting
0
Completed
2
Sites
3
Countries
2
Endpoints
116
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 116 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 7 of 116 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
3
2
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| CARPE_DIEMCognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway | Sirolimus Alzheimer’s disease | Alzheimer's disease | Early Ph 1 | Completed | 1 | Jan 2022 | 1 | results |
| REACHRapamycin - Effects on Alzheimer's and Cognitive Health | Sirolimus Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Ph 2 | Active, not recruiting | 1 | Mar 2026 | - | |
| ERAPEvaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography | Sirolimus Alzheimer’s disease | Alzheimer's disease | Ph 1/2 | Completed | 1 | Dec 2024 | 2 |
Showing 1-3 of 3 trials